Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

CRISPR Therapeutics AG (CRSP) has recently been on ... between trends in earnings estimate revisions and short-term stock price movements. Powered by Money.com - Yahoo may earn commission from ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) has recently been on ... between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, CRISPR Therapeutics is expected ...

If an investor was to purchase shares of CRSP stock at the current price level of $35.23/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most ... strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the ...

The analyst forecasts on MarketBeat have a Moderate Buy rating on the stock with a $71.75 price target that is over 100% above the CRSP stock price on May 15, 2025. That tells you that CRSPR isn ...

Analysts arrive at stock ratings after doing extensive ... with a price target of $86.00 to $86.00. The current price CRISPR Therapeutics (CRSP) is trading at is $36.60, which is out of the ...

Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while ...